ALEXANDRIA, Va. -- Twenty-seven practices elevated their standard of care and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. The Association for Clinical Oncology (Association) commends these practices that have demonstrated their commitment to providing the highest-quality oncology care to their patients, communities, and contemporaries.
Researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world are among the recipients of the American Society of Clinical Oncology’s (ASCO) Special Awards – the Society’s highest honors - and Conquer Cancer, the ASCO Foundation Women Who Conquer Cancer Mentorship Awards.
ASCO today announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on the coronavirus’ effect on individuals with cancer, and set forth a road to recovery as the cancer care delivery system prepares for life after COVID-19.
ASCO today launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes.
The American Society of Clinical Oncology (ASCO) today released a set of recommendations to support the oncology community as health care institutions across the United States face potentially difficult decisions around the allocation of scarce health care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is expected to demand more resources—including ventilators, critical and intensive care beds, and medications—than the U.S. or local health care systems can supply, and institutions will need to develop allocation decision policies as they provide care for a growing number of patients.
“We commend the U.S. Food and Drug Administration (FDA) for releasing draft guidance to encourage the inclusion of older adults in clinical trials of drugs for the treatment of cancer. We thank Richard Pazdur, MD, director of the FDA Oncology Center of Excellence, for his leadership on this important issue.
Clinical trials often provide patients with life-threatening conditions the best - perhaps only - treatment option for their condition. However, unlike Medicare and private and commercial payers, Medicaid is not federally required to cover routine care costs (like physician visits and laboratory studies) for patients on clinical trials.
Roswell Park Comprehensive Cancer Center of Buffalo, N.Y., has just signed an agreement to use the CancerLinQ® platform.
ASCO released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to ensure that these programs are implemented appropriately, with sufficient patient protections in place.
Today, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring.
Thirty-three practices in three countries have committed to providing high quality care by receiving the Quality Oncology Practice Initiative (QOPI®) Certification in the fourth quarter of 2019. The Association for Clinical Oncology (Association) applauds the work of these practices to ensure a better and healthier future.
2019-20 ASCO President Howard Burris III commends CMS for reflecting recommendations in the Society’s position statement on pharmacy benefit managers in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.
The emergence of novel systemic therapies — combined in new and better ways — has significantly changed the role of cancer surgery. In recognition of the substantial progress made in this area in the past year, in Clinical Cancer Advances 2020 — just released today— the American Society of Clinical Oncology (ASCO) has named is the Refinement of Surgical Treatment of Cancer as the Advance of the Year.
The American Society of Clinical Oncology released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid—or block grants—could have on patients with cancer.
Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25, 2020 at the Moscone West Building in San Francisco, California.